

# Laurent Gilardin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2017953/publications.pdf>

Version: 2024-02-01

29  
papers

4,908  
citations

566801

15  
h-index

433756

31  
g-index

33  
all docs

33  
docs citations

33  
times ranked

9570  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,983
2	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,749
3	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	5.6	357
4	High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. <i>Brain</i> , 2016, 139, 2131-2135.	3.7	202
5	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	3.3	110
6	Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. <i>Cell Reports Medicine</i> , 2020, 1, 100016.	3.3	102
7	Intravenous immunoglobulin as clinical immune-modulating therapy. <i>Cmaj</i> , 2015, 187, 257-264.	0.9	74
8	Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immune-Mediated Inflammatory Diseases. <i>Arthritis Care and Research</i> , 2013, 65, 1504-1514.	1.5	43
9	Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 524-535.e8.	1.5	36
10	Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. <i>Scientific Reports</i> , 2014, 4, 5672.	1.6	31
11	Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy. <i>Cell Death and Disease</i> , 2020, 11, 50.	2.7	30
12	Symptomatic muscular sarcoidosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e452.	3.1	27
13	Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1729-1742.	1.8	24
14	<i>In silico</i> calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. <i>Haemophilia</i> , 2014, 20, 176-184.	1.0	20
15	Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma. <i>Cancer Radiotherapy: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 132-137.	0.6	19
16	Complement C3 is a novel modulator of the anti-factor VIII immune response. <i>Haematologica</i> , 2018, 103, 351-360.	1.7	17
17	The ADAMTS13 <sup>1239-1253</sup> peptide is a dominant HLA-DR1-restricted CD4 <sup>+</sup> T-cell epitope. <i>Haematologica</i> , 2017, 102, 1833-1841.	1.7	14
18	Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group. <i>American Journal of Hematology</i> , 2019, 94, E183-E185.	2.0	12

#	ARTICLE	IF	CITATIONS
19	Predictive immunogenicity of Refact <sup>o</sup> AF. Haemophilia, 2014, 20, 486-492.	1.0	11
20	Peripheral T-cell lymphoma in HIV-infected patients: a study of 17 cases in the combination antiretroviral therapy era. British Journal of Haematology, 2013, 161, 843-851.	1.2	9
21	Pauci-immune Crescentic Glomerulonephritis Associated With ANCA of IgA Class. American Journal of Kidney Diseases, 2009, 53, 1063-1067.	2.1	6
22	Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity. Acta Oncologica, 2020, 59, 484-489.	0.8	4
23	Wrist-worn accelerometer as innovative tool for longitudinal follow-up of idiopathic inflammatory myopathy patients: A pilot study. Neuromuscular Disorders, 2015, 25, S310.	0.3	3
24	Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients. Journal of Immunology, 2016, 196, 4075-4081.	0.4	3
25	Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy?. Leukemia and Lymphoma, 2019, 60, 547-549.	0.6	3
26	IVIg Treatment Reduces Catalytic Antibody Titers of Renal Transplanted Patients. PLoS ONE, 2013, 8, e70731.	1.1	3
27	Interferon± Inhibition by Intravenous Immunoglobulin Is Independent of Modulation of the Plasmacytoid Dendritic Cell Population in the Circulation: Comment on the Article by Wiedeman et al. Arthritis and Rheumatology, 2014, 66, 2308-2309.	2.9	2
28	Kinase Inhibitors (ibrutinib or idelalisib) in the Management of Chronic Lymphocytic Leukemia-Associated Autoimmune Cytopenia: A Retrospective Study of the French Innovative Leukemia Organization (FILO). Blood, 2018, 132, 3152-3152.	0.6	1
29	Identification of T Cell Epitope of ADAMTS13 in Thrombotic Thrombocytopenic Purpura Patients. Blood, 2015, 126, 106-106.	0.6	1